Compare Cytokinetics Inc (CYTK) vs VICI Properties Inc (VICI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs VICI Properties Inc — how do they compare? Cytokinetics Inc trades at $62.02 (market cap $8.50B), while VICI Properties Inc trades at $22.88 (market cap $24.93B). The key difference: VICI Properties Inc is far larger — about 2.9× Cytokinetics Inc's market cap, and VICI Properties Inc pays a 8.13% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and VICI Properties Inc for 42 Days on average.
| CYTK | VICI | |
|---|---|---|
Market Cap | $8.50B | $24.93B |
Volume | 2,395,556 | 9,679,693 |
Sector | Health | Real Estate |
52-Week High | $87.26 | $31.42 |
52-Week Low | $54.76 | $22.53 |
Typical Hold Time | 19 Days | 42 Days |
Enterprise Value | $8.60B | $42.48B |
Dividend Yield | — | 8.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CYTK trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages but bullish momentum from oscillators. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy, including Phase 3 results and real-world study launches.
Despite heavy losses, strong analyst consensus (97.14% buy ratings) and a $112.50 price target reflect optimism for its heart failure pipeline. Key risks include sustained cash burn, competitive pressure from Bristol Myers Squibb's Camzyos, and the need for successful commercialization to justify its high P/S ratio of 112.42.
VICI Properties trades at $22.64, down 0.4% on the day, with a bearish technical signal driven by moving averages. The stock shows attractive valuation metrics, including a P/E of 8.78 and P/B of 0.85, alongside strong profitability with a net income margin of 67.5%. Recent earnings have been mixed, with a beat in Q1 2026 but misses in Q4 2025 and Q2 2026. The company maintains robust cash flow from operations of $2.51 billion in 2025 and recently announced a dividend of $0.46 per share payable in October 2026.
The outlook for VICI is supported by solid fundamentals and a 75% analyst buy rating, with a consensus price target of $28.90 implying significant upside. However, risks include tenant concentration concerns, as highlighted in recent news, and the bearish technical trend. The stock offers value and income potential but faces headwinds from market sentiment and interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
